OptimizeRx Corporation reported a significant financial turnaround in its fiscal year ending December 31, 2025, achieving a net income of $5.1 million compared to a net loss of $20.1 million in the previous year. This improvement was driven by a 19% increase in net revenue, which rose to $109.4 million from $92.1 million in 2024. The company's gross profit also saw a notable increase, reaching $73.6 million, up from $59.4 million, reflecting a gross margin improvement from 64.5% to 67.3%. The reduction in operating expenses to $61.9 million from $73.1 million contributed to this positive shift in profitability.
The company experienced a notable change in its customer base, with its top five customers accounting for approximately 47% of total revenue in 2025, down from 49% in 2024. This shift indicates a diversification in its revenue sources, although it remains heavily reliant on a concentrated group of pharmaceutical manufacturers. The company also reported a decrease in average revenue per top 20 pharmaceutical manufacturers, attributed to lower revenue from these key accounts, while onboarding new customers contributed to overall revenue growth.
Strategically, OptimizeRx expanded its capabilities through the acquisition of Healthy Offers, Inc. (Medicx Health) in October 2023, which enhanced its direct-to-consumer marketing offerings. The integration of Medicx Health allowed the company to leverage its patented Micro-Neighborhood® Targeting solution, enabling more precise audience targeting for pharmaceutical brands. The company is also transitioning its Dynamic Audience Activation Platform (DAAP) customers to a subscription-based model, which is expected to improve revenue predictability and margins over time.
Operationally, OptimizeRx reported a total employee count of 132 as of December 31, 2025, with a focus on enhancing productivity. The company’s revenue per average full-time employee increased, indicating improved efficiency. Additionally, the company maintained a strong liquidity position, with total current assets of $64.7 million against current liabilities of $21.3 million, resulting in a current ratio of 3.0. This financial stability supports its ongoing operations and potential future growth initiatives.
Looking ahead, OptimizeRx aims to continue its growth trajectory by enhancing its technology solutions and expanding its market presence. The company is focused on achieving a sustainable "Rule of 40" status, where its combined annual revenue growth rate and adjusted EBITDA margin exceed 40%. However, the company acknowledges potential risks, including economic uncertainties and regulatory changes that could impact its operations and financial performance.
About OptimizeRx Corp
OptimizeRx Corporation is a healthcare technology company specializing in digital marketing solutions for the life sciences industry. It offers AI-driven audience targeting, omnichannel engagement, and patient and provider communication platforms. Serving pharmaceutical manufacturers and healthcare providers, it enhances brand visibility, patient access, and treatment support through proprietary data, privacy-safe targeting, and integrated digital channels. Its business model focuses on innovative, scalable solutions to improve healthcare marketing and patient outcomes.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.